NCT06736769
Ketamine Effects on Learning In Eating Disorders
Enrolling by Invitation
PHASE2Ages 16–26InterventionalTreatmentAmanda Downey, MDInvestigator-initiated
~20 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Ketamine infusion
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean Change From Baseline in Reversal Learning
Measured over Day 2, Day 4
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Amanda E. Downey, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Mean Change From Baseline in Reversal LearningDay 2, Day 4
Mean change in reversal learning as measured by the probabilistic reversal learning task.In the task, participants are presented with two stimuli, told to choose one of the two stimuli on each trial, and receive feedback regarding whether the stimulus is "Correct" or "Incorrect." Participants must modify their choice based on c hanging stimulus-outcome contingencies over time, engaging flexible learning.